Literature DB >> 24673331

The vitamin D receptor turns off chronically activated T cells.

Margherita T Cantorna1, Amanda Waddell.   

Abstract

T cell proliferation and T helper (TH ) cells that make IL-17 (TH 17 cells) and IFN-γ (TH 1 cells) have been shown to be inhibited by 1,25(OH)2 D3 . Previous work has shown that immune-mediated diseases, where TH 1 and TH 17 cells are pathogenic, are ameliorated with 1,25(OH)2 D3 treatment. Paradoxically, infectious diseases that require TH 1 and TH 17 responses for host resistance are unaffected by 1,25(OH)2 D3 treatment. Resting T cells are not responsive to vitamin D because they do not express the vitamin D receptor (VDR) until late after activation. T cells activated following an infection help clear the infection, and since the antigen is eliminated, vitamin D is not needed to dampen the immune response. Conversely, in immune-mediated disease, there is chronic T cell activation, and in this scenario, vitamin D and 1,25(OH)2 D3 are critical for inhibiting T cell proliferation and cytokine production. Vitamin D is a late regulator of T cell function and acts to turn off T cells. This paper will review these data.
© 2014 New York Academy of Sciences.

Entities:  

Keywords:  CD8 T cells; TH17; inflammatory bowel diseases; vitamin D

Mesh:

Substances:

Year:  2014        PMID: 24673331     DOI: 10.1111/nyas.12408

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  36 in total

1.  The Role of Integrin Expressing Cells in Modulating Disease Susceptibility and Progression (January 2016).

Authors:  Aftab A Ansari; Siddappa N Byrareddy
Journal:  Int Trends Immun       Date:  2016-01

2.  Vitamin D: A Modulator of Allergic Rhinitis.

Authors:  Sunita Agarwal; Shashank Nath Singh; Rohtash Kumar; Ritu Sehra
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2019-06-27

3.  Vitamin D treatment modulates immune activation in cystic fibrosis.

Authors:  T Pincikova; D Paquin-Proulx; J K Sandberg; M Flodström-Tullberg; L Hjelte
Journal:  Clin Exp Immunol       Date:  2017-05-24       Impact factor: 4.330

4.  Does Vitamin D Protect the Gut Mucosal Barrier? Mechanistic Insights from Experimental Colitis.

Authors:  Maria O'Sullivan
Journal:  Dig Dis Sci       Date:  2015-05-19       Impact factor: 3.199

5.  AT1R blockade in adverse milieus: role of SMRT and corepressor complexes.

Authors:  Tejinder Singh; Kamesh Ayasolla; Partab Rai; Nirupama Chandel; Shabirul Haque; Rivka Lederman; Mohammad Husain; Vasupradha Vethantham; Amrita Chawla; Himanshu Vashistha; Moin A Saleem; Guohua Ding; Praveen N Chander; Ashwani Malhotra; Leonard G Meggs; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-17

Review 6.  Aligning the Paradoxical Role of Vitamin D in Gastrointestinal Immunity.

Authors:  Margherita T Cantorna; Connie J Rogers; Juhi Arora
Journal:  Trends Endocrinol Metab       Date:  2019-05-20       Impact factor: 12.015

7.  A SPECIAL MEETING REVIEW EDITION: CCFA/Advances in Inflammatory Bowel Diseases 2015: Highlights in Ulcerative Colitis and Crohn's Disease: A Review of Selected Presentations From the CCFA/Advances in Inflammatory Bowel Diseases 2015 Clinical and Research Conference • December 10-12, 2015 • Orlando, FloridaSpecial Reporting on:• New and Future Adhesion Molecule-Based Therapies in IBD• Efficacy and Safety of Vedolizumab for Inflammatory Bowel Disease in Clinical Practice• A Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-Severe Crohn's Disease Refractory to Anti-TNFα: UNITI-1• Intravenous Iron Sucrose for Treatment of Iron Deficiency Anemia in Pediatric Inflammatory Bowel Disease• Does Vedolizumab Affect Postoperative Outcomes in Patients Undergoing Abdominal Operations for Inflammatory Bowel Disease?PLUS Meeting Abstract Summaries With Expert Commentary by: Gary R. Lichtenstein, MDProfessor of MedicineDirector, Center for Inflammatory Bowel DiseaseUniversity of Pennsylvania Health SystemHospital of the University of PennsylvaniaPhiladelphia, Pennsylvania.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-02

8.  Maternal and Newborn Vitamin D-Binding Protein, Vitamin D Levels, Vitamin D Receptor Genotype, and Childhood Type 1 Diabetes.

Authors:  German Tapia; Karl Mårild; Sandra R Dahl; Nicolai A Lund-Blix; Marte K Viken; Benedicte A Lie; Pål R Njølstad; Geir Joner; Torild Skrivarhaug; Arieh S Cohen; Ketil Størdal; Lars C Stene
Journal:  Diabetes Care       Date:  2019-01-28       Impact factor: 19.112

9.  Vitamin D and Lung Infection.

Authors:  Margherita T Cantorna
Journal:  Infect Immun       Date:  2016-10-17       Impact factor: 3.441

10.  Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes.

Authors:  Kristine C Olson; Paige M Kulling Larkin; Rossana Signorelli; Cait E Hamele; Thomas L Olson; Mark R Conaway; David J Feith; Thomas P Loughran
Journal:  Cytokine       Date:  2018-11-17       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.